Mark Colonnese - Atea Pharmaceuticals CFO, Executive Vice President

AVIR -  USA Stock  

USD 24.78  0.33  1.31%

  President
Mr. Mark P. Colonnese is Chief Financial Officer, Executive Vice President of the Company. He served as the Chief Financial Officer of Stealth BioTherapeutics since November 2014 and as the Executive Vice President and Chief Financial Officer of Transgenomic Inc. from August 2012 to October 2014. Prior to that, he worked at Salutria Pharmaceuticals, LLC and at its predecessor company, AtheroGenics Inc., from 1999 to 2012, where he served in a number of executive roles, most recently as Executive Vice President, Commercial Operations and Chief Financial Officer. He has also held executive positions at Applied Analytical Industries and ScheringPlough, and served on the Board of Directors of Endeavor Pharmaceuticals, Inc
Age: 60  President Since 2015  MBA    
678 221-3343  www.aviragentherapeutics.com
Colonnese holds an M.B.A. Degree from Fairleigh Dickinson University and a B.S. magna cum laude from Ithaca College. He is a Certified Public Accountant .

Mark Colonnese Latest Insider Activity

Tracking and analyzing the buying and selling activities of Mark Colonnese against Atea Pharmaceuticals stock is an integral part of due diligence when investing in Atea Pharmaceuticals. Mark Colonnese insider activity provides valuable insight into whether Atea Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Atea Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Atea Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Atea Pharmaceuticals Management Efficiency

Atea Pharmaceuticals has return on total asset (ROA) of 1.7 % which means that it generated profit of $1.7 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (3.86) %, meaning that it created substantial loss on money invested by shareholders. Atea Pharmaceuticals management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. As of 07/26/2021, Return on Invested Capital is likely to grow to 0.07, while Return on Investment is likely to drop (20.28) . Atea Pharmaceuticals Total Assets are relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Total Assets of 863.63 Million. As of 07/26/2021, Current Assets is likely to grow to about 931.6 M, while Net Current Assets as percentage of Total Assets are likely to drop 102.91.
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Found 10 records

PRESIDENT Since

Steven KatesDicerna Pharmaceutic
2019
David JohnsonDynavax Technologies
2014
Paul PapiDiamedica Therapeutics
2016
Theodore AshburnDicerna Pharmaceutic
2014
Michael OstrachDynavax Technologies
2016
Robert JanssenDynavax Technologies
2018
Bruce SteelEquillium
2018
Hardean AchneckDicerna Pharmaceutic
2019
Ryan SpencerDynavax Technologies
2019
Regina PagliaDicerna Pharmaceutic
2019
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people. Atea Pharmaceuticals (AVIR) is traded on NASDAQ Exchange in USA. It is located in 2500 Northwinds Parkway Suite 100, Alpharetta, GA 30009, United States and employs 39 people. Atea Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Atea Pharmaceuticals Leadership Team

Elected by the shareholders, the Atea Pharmaceuticals' board of directors comprises two types of representatives: Atea Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atea Pharmaceuticals. The board's role is to monitor Atea Pharmaceuticals' management team and ensure that shareholders' interests are well served. Atea Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atea Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
John Richard, Independent Director
Anne VanLent, Independent Director
Mark Colonnese, CFO, Executive Vice President
Russell Plumb, Executive Chairman of the Board
Michael Dunne, Independent Director
Joseph Patti, President CEO, Director
Armando Anido, Independent Director
Geoffrey Cox, Independent Director
Michael Dougherty, Independent Director

Atea Pharmaceuticals Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Atea Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Atea Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Valuation Now

   

Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Atea Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Atea Pharmaceuticals and Equillium. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.